effectively neutralise SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains.”The biotechnology company said in a statement that coronavirus variants “have multiple mutations in their spike or S glycoproteins, which are key targets of virus neutralising antibodies”.effectively neutralise SARS-CoV-2,” the company said.
Even though the findings from the experiment were limited, this still indicated that the key N501Y mutation, found in the emerging UK and South Africa variants, did not create resistance to the Pfizer-BioNTech vaccine-induced immune responses, explained the researchers. “Further data is needed to monitor the Pfizer-BioNTech Covid-19 vaccine’s effectiveness in preventing Covid-19 caused by new virus variants,” they said.
Be warned...